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Preface  
This PhD thesis concludes my work through the last three years employed as an industrial PhD 
student at Novo Nordisk A/S. The project is a collaboration between Novo Nordisk A/S and 
Aalborg University and was co-funded by the Danish Ministry of Science, Technology and 
Innovation and Novo Nordisk A/S.  
 
In this PhD thesis it is explored how hypoglycaemia in type 1 diabetes affects cardiac 
repolarisation. Furthermore, the physiological mechanisms governing this phenomenon are 
investigated. 
 
In addition to this work, a substantial amount of time has been spent on exploiting the data 
and knowledge obtained through the PhD for development of technology for improving the 
treatment of diabetes. As this technology is bound by confidentiality agreements and 
intellectual property rights it will only be disclosed under confidentiality. A separate 
confidential technical report describing this work is thus included as a part of the PhD thesis. 
 
The PhD thesis consists of the following in parts: 
 An introduction where the problem background is described which is concluded by the 
aims and hypotheses of the PhD project. 
 Four scientific articles describing the main scientific findings of the PhD project.  
 A discussion of the findings in the articles and a conclusion on the hypotheses. 
 A separate confidential technical report. 
 
In the electronic edition of the thesis, part 2 and 4 are excluded due to copyright and 
confidentiality, respectively. 
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Abstract 
The ‘dead in bed’ syndrome is a condition where otherwise healthy young people 
with type 1 diabetes are found dead in the morning in an undisturbed bed. It has been 
hypothesized that the phenomenon may be caused by hypoglycaemia triggering cardiac 
arrhythmia. This hypothesis has been strengthened with findings of QT interval prolongation 
during hypoglycaemia. QT interval prolongation has been associated with an increased risk of 
cardiac death in several subpopulations including patients with diabetes. This PhD thesis 
investigates changes in the QT interval and cardiac repolarisation during hypoglycaemia as well 
as the underlying physiological mechanisms. 
 
In Paper I, different sources of variation when investigating the heart rate corrected QT 
interval (QTc) during hypoglycaemia were explored. Hypoglycaemia was induced by an 
intravenous bolus of insulin in persons with type 1 diabetes and the differences between QT 
interval measuring techniques, types of insulin and heart rate correction formulas were 
studied. The results suggested that the measurement technique has a profound effect on the 
QT interval prolongation seen during hypoglycaemia. Heart rate correction also affected the 
degree of prolongation during hypoglycaemia. 
 
In Paper II, the changes in QTc during spontaneous hypoglycaemia were investigated. 21 adults 
with type 1 diabetes were monitored for 72 hours using a continuous glucose monitor and a 
Holter monitor with the aim of capturing spontaneous episodes of hypoglycaemia. In addition 
to quantifying the QTc during hypoglycaemia the performance of several QT interval correction 
formulas was explored. Spontaneous hypoglycaemia was only associated with significant 
prolongation of QTc using Bazett’s formula, the most popular heart rate correction formula. 
The other applied correction formulas did not show a significant prolongation. 
 
In Paper III, hypoglycaemia was induced by subcutaneous insulin injection to build a bridge 
between the results from hypoglycaemic clamp studies and studies of spontaneous 
hypoglycaemia. Ten adults with type 1 diabetes were studied and QTc, adrenaline and 
potassium were measured to investigate both the prolongation of QTc during hypoglycaemia 
and the underlying physiological mechanisms. The results showed significant prolongation of 
the QTc, however the prolongation was smaller than seen during typical clamp studies. 
 
In Paper IV, we developed a physiological model of changes in potassium during 
hypoglycaemia to get a deeper understanding of the physiological mechanisms responsible for 
QT interval prolongation. The model was developed and tested on data from the literature. 
The tests showed that the model was able to simulate potassium in a range of situations, 
although rapid changes in insulin and adrenaline were associated with larger simulation errors. 
 
In this PhD thesis I showed that the degree of QTc prolongation seen during hypoglycaemia is 
dependent on both measurement technique and heart rate correction (Paper I+II+III). I found 
that QTc prolongation during spontaneous hypoglycaemia may be due to overcorrection by 
Bazett’s formula (Paper II). I presented a novel methodology for studying QTc during controlled 
but realistic episodes of hypoglycaemia, which showed significant QTc prolongation during 
hypoglycaemia compared with control episodes (Paper III). Lastly, I developed a physiological 
model of potassium to gain new knowledge on the physiological mechanisms behind the 
proposed QT interval prolongation during hypoglycaemia (Paper IV). 
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Abbreviations 
ADA American Diabetes Association 
BG Blood glucose (concentration) 
BGM Blood glucose measurement 
BPM Beats per minutes 
CGM Continuous Glucose Monitor. 
ECG Electrocardiogram. 
IG Interstitial glucose concentration 
MA Manual annotation (method for QT interval measurement) 
QRS complex Collective duration of the Q, R and S waves in the ECG. The QRS complex 
constitutes the duration of the depolarisation of the heart. 
QT interval The time from the onset of the Q wave to the end of the T wave in the ECG. 
QTc The heart rate corrected QT interval 
QTcB The heart rate corrected QT interval using Bazett’s formula 
QTcF The heart rate corrected QT interval using Fridericia’s formula 
QTcN The heart rate corrected QT interval using the Nomogram method 
QTcS The heart rate corrected QT interval using a subject specific method 
RR interval The time between two consecutive R waves in the ECG. 
SI Slope intersect (method for QT interval measurement) 
SMBG Self monitoring of blood glucose 
T1DM Type 1 diabetes mellitus 
T2DM Type 2 diabetes mellitus 
T/R Ratio The amplitude ratio between the T wave peak and the R wave peak in the 
ECG 
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INTRODUCTION 
Diabetes Mellitus is a global epidemic. The prevalence of the disease is estimated to reach 285 
million in 2010 corresponding to 6.6% of the world population.1 By 2030, 7.8% of the world 
population or 438 million people are expected to have the disease.1 In 2010, diabetes will be 
responsible for an estimated 4 million deaths or 6.8% of all deaths globally.1 The estimated 
global healthcare expenditures to treat and prevent diabetes and its complications are 
expected to reach $376 billion in 2010.1 In addition to economic costs, diabetes is associated 
with physical and psychological morbidity and decreased quality of life. The odds of depression 
double in the presence of diabetes.2  
Diabetes 
Diabetes is a collection of diseases characterised by insufficient insulin production and/or 
insulin resistance. Insulin is a hormone that mediates the uptake of glucose in liver, muscle and 
fat tissue. The lack of insulin or insulin resistance results in elevated blood glucose 
concentration (BG), hyperglycaemia, which is the cardinal symptom of diabetes. On the long 
term, hyperglycaemia causes damage to nerves and blood vessels resulting in a number of 
microvascular and macrovascular complications. The two major types of diabetes are type 1 
(T1DM) and type 2 (T2DM) constituting approximately 10% and 90% of the total diabetes 
population, respectively. A small proportion (3-5%) of pregnant women develops gestational 
diabetes (GDM) that resembles T2DM in manifestation and aetiology.3 GDM along with other 
types of the disease including pre-diabetes will not be discussed further in this report. 
Type 1 diabetes  
In T1DM, a progressive destruction of the insulin producing beta cells in the pancreas causes 
an absolute insulin deficiency. Therefore, people with T1DM are dependent on daily insulin 
injections. Without exogenous insulin people with T1DM will die from ketoacidosis within a 
short time. The incidence rate of T1DM peaks in the second decade of life and levels out in the 
third and fourth but increases again thereafter. The cumulative incidence rate by age 70 is 1%. 
The pathogenesis of T1DM is still largely unknown. A number of genetic mutations have been 
associated with the development of the disease but twin studies suggest that genetic factors 
can only partly explain the development of the disease. A number of environmental factors 
including viral infections have been suggested to trigger the disease.4 
Type 2 diabetes  
T2DM, the most common type of diabetes, is characterised by impaired insulin sensitivity and 
secretion. Unlike T1DM, persons with T2DM retain a certain production of insulin although 
insufficient to keep the BG within normal range. T2DM progresses slowly and as a result 
people can have the disease for years without knowing it. Treatment of T2DM starts with oral 
medication that increases insulin sensitivity but as the disease progresses it is often necessary 
to treat with insulin injections. The incidence rate increases with age with a cumulative 
incidence rate by age 70 of 11 %. The major risk factors for developing T2DM are obesity and a 
family history of the disease.4 
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Treatment of diabetes 
The treatment of diabetes is focused on maintaining BG within the normal range of a healthy 
person (4-7mmol/l). In T1DM and in the later stages of T2DM, subcutaneous injections of 
insulin are needed several times daily. Insulin therapy aims at mimicking the insulin secretion 
of healthy people. The multiple daily injection (MDI) treatment regime recommended by the 
American Diabetes Association (ADA) comprises long acting insulin for maintaining a basal 
level and fast acting insulin in conjunction with meals.5  
There is conclusive evidence that intensive insulin therapy aiming at elimination of 
hyperglycaemia reduce the risk of the long term complications associated with diabetes.6 
Effectiveness of insulin treatment is measured using the percentage of glycosylated 
hemoglobin, HbA1c, which indicates the average BG over the past few months. There is a close 
link between HbA1c and the risk of developing long term complications such as retinopathy, 
nephropathy and neuropathy. In Figure 1a, the rate of progression of retinopathy is shown to 
increase with increasing values of HbA1c. The ADA recommends a target level of HbA1c of < 
7%, however this is achieved only for the minority of persons with T1DM.5 The problem is that 
keeping a low HbA1c increases the risk of hypoglycaemia (Figure 1b).6  
 
Figure 1. (a) The relationship between HbA1c and the rate of progression of retinopathy. (b) The 
relationship between HbA1c and the rate of severe hypoglycaemia.
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Hypoglycaemia 
Hypoglycaemia is the limiting factor in achieving optimal glycaemic control in T1DM. If it was 
not for the risk of hypoglycaemia, people with diabetes could avoid high HbA1c levels and a 
normal life except for taking their medication.7 The reality is however that the risk of 
hypoglycaemia imposes several limitations in the everyday life of people with diabetes. 
Alcohol, exercise, missed or skipped meals and bad timing of insulin injections are all frequent 
causes of hypoglycaemia in T1DM. The prospect of experiencing a severe episode of 
hypoglycaemia where help from others are needed causes psychological morbidity in both the 
person with diabetes as well as family and relatives. Although rare, hypoglycaemia can be fatal 
and it is estimated that 2%-6% of deaths in diabetes can be attributed to hypoglycaemia.8 The 
problem faced by people with diabetes is that a lower HbA1c will reduce the risk of developing 
long term complications but it also increases the risk of severe hypoglycaemia as seen in Figure 
1b. 
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Definition 
There exists no clear definition of hypoglycaemia. ADA defines hypoglycaemia as BG of 3.9 
mmol/l or below.5 This definition is however more a guideline to which levels of BG should be 
avoided and not a strict definition of physiological hypoglycaemia.9 Whipple’s triad adapted for 
diabetes (Table 1) is more appropriate for the definition of hypoglycaemia.10 
Table 1. Whipple’s triad adapted for diabetes from Watkins et al.
10
 
 
Criteria of Hypoglycaemia 
1. Symptoms or signs compatible with low BG 
2. Blood glucose <3.5mmol/L 
3. Relief of symptoms and signs by restoration of 
circulating blood/plasma glucose concentrations 
Ideally, to diagnose hypoglycaemia, all three criteria from Table 1 should be fulfilled. That is, 
there should be symptoms or signs of hypoglycaemia (including signs not recognised by the 
person with diabetes), a confirmatory blood glucose measurement and relief of symptoms and 
signs when the BG is restored to normal level. In reality, it may be difficult to ensure fulfilment 
of all three criteria in a clinical setting since symptoms and signs are subjective and different in 
individuals. Likewise the BG level at which a person experience symptoms and signs of 
hypoglycaemia has a large inter-person as well as intra-person variability, depending on 
several factors such as duration of diabetes, glycaemic control and antecedent 
hypoglycaemia.11  
When assessing the severity of hypoglycaemia, episodes are often divided into the four 
categories listed in Table 2.9 The definitions in Table 2 have gained wide acceptance when 
characterising episodes of hypoglycaemia both in diabetes research and in management of 
diabetes. 
Table 2. Clinical definitions of hypoglycaemia from Strachan.
9
 
 
Definition Description 
Asymptomatic 
Low BG identified on routine blood test, with no 
associated symptoms 
Mild 
Symptoms suggestive of hypoglycaemia; episode 
successfully treated by the patient alone. 
Severe 
Assistance from a third party is required to effect 
treatment 
Profound Associated with permanent neurological deficits or death 
Setting a specific biochemical definition of hypoglycaemia is not possible without the risk of 
false positives or negatives. However, when investigating asymptomatic episodes of 
hypoglycaemia a biochemical definition needs to be set. 
Frequency 
In persons with T1DM striving for glycaemic control, it is estimated that asymptomatic 
hypoglycaemia (< 3.3 mmol/l) may be present 10% of the time.12 It is however difficult to 
estimate the frequency of asymptomatic hypoglycaemia because it depends on the sampling 
of BG or the use of continuous glucose monitors which may be inaccurate. In fact, the use of 
continuous glucose monitors might overestimate the frequency of or time in 
hypoglycaemia.13,14 On average, in T1DM, mild episodes of hypoglycaemia are present two 
times every week while severe, temporally disabling episodes occur once every year.9,12 
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Frequency of hypoglycaemia is substantially lower in T2DM than in T1DM. In T2DM patients 
treated with oral agents only 2-3% experience severe hypoglycaemia while the number for 
insulin treated T2DM patients is 11%. For comparison, 65% of intensively treated T1DM 
patients experience severe hypoglycaemia.12 
Counterregulation to hypoglycaemia 
As BG falls below a certain level a series of physiological mechanisms occur to raise BG to 
normal levels. These mechanisms are collectively known as counterregulation to 
hypoglycaemia. In Figure 2 the different mechanisms of counterregulation are shown along 
with the glucose level at which they are initiated. The first counterregulatory mechanism in 
non-diabetic persons is a reduction in insulin secretion – a mechanism absent in T1DM due to 
absence of endogenous insulin production. The second mechanism in the counterregulatory 
response is the release of glucagon, a hormone that, antagonistic to insulin, stimulates 
glucogenolysis and gluconeogenesis while inhibiting glucogenesis. In T1DM, the glucagon 
secretory response to hypoglycaemia is lost within a few years of onset of the disease. The 
third counterregulatory response is the release of epinephrine, cortisol and growth hormone. 
Only epinephrine has an effect on acute hypoglycaemia by raising the BG and producing 
warning symptoms. For most people with T1DM an attenuated epinephrine response remains 
as the only counterregulatory response before BG drops to a level where cognitive function is 
affected. When blood glucose gets below 2 mmol/l increased cerebral blood and hepatic 
autoregulation set in. The consequence of an impaired counterregulation is that people with 
T1DM will develop hypoglycaemia much faster with less warning symptoms resulting in a 
significantly increased risk of severe or profound hypoglycaemia.11 
 
Figure 2. BG thresholds for counterregulatory mechanisms including release of hormones and onset 
of warning symptoms and cognitive impairment.
15
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Cardiac Arrhythmia and hypoglycaemia 
Tattersall and Gill reported in the early 1990’s a series of unexplained nocturnal sudden deaths 
of young people with T1DM.16 This phenomenon was named the ‘dead in bed’ syndrome and 
evidence suggested that it was caused by hypoglycaemia, since the patients had a history of 
severe hypoglycaemia. The patients were found in an undisturbed bed which led to the 
hypothesis that fatal cardiac arrhythmia had been triggered by hypoglycaemia.17 Since the 
phenomenon is very rare (an estimated 2-6 cases per 10.000 patient years18) it is impossible to 
make observational studies on actual cases. In stead several studies have investigated the 
effect of induced and spontaneous hypoglycaemia on the cardiovascular function and in the 
electrocardiogram. Hypoglycaemia has been associated with atrial fibrillation19 but the most 
significant finding has been an altered cardiac repolarisation during hypoglycaemia manifest as 
a prolonged QT interval.20,21,22,23,24,25,26,27,28 A prolonged QT interval during hypoglycaemia is an 
important finding since prolongation of the QT interval is known as an independent cardiac risk 
factor for sudden death and Torsade the Pointes (TdP) tachycardia.29,30,31,32,33,34,35  
The QT interval 
The QT interval is measured on the surface ECG and is defined as the onset of the Q wave to 
the end of the T wave (Figure 3).  
 
Figure 3. Illustration of the ECG from one beat cycle with the associated waves and the QT interval.   
The QT interval comprises the QRS interval (depolarisation of the ventricles) and the T wave 
(repolarisation of the ventricles) and is in general perceived as a measure of the repolarisation 
duration of the ventricles as the QRS interval shows little variation in the normal ECG. 
The heart rate corrected QT interval (QTc) has been subject of intense research for decades. 
Prolongation of the QT interval has been reported as a risk factor for cardiac death in patients 
with heart failure36, myocardial infarction37, type 1 diabetes35,38,39, type 2 diabetes33 and in the 
general population40,34,29. There is thus evidence to suggest a correlation between prolongation 
of the QT interval and cardiac death although others have questioned the prognostic value of a 
QT prolongation in the general population31,41,42. Prolongation of the QT interval can be either 
congenital or acquired. The congenital long QT syndrome is a rare disease caused by mutations 
of genes affecting the ion channels involved in the repolarisation of cardiac myocytes. 
Acquired long QT on the other hand is more common and is mostly caused by different 
medications32,43 (in particular antiarrhythmic and antipsychotic drugs) although conditions as 
hypokalaemia44 and hypoglycaemia22 also have been reported to cause acquired long QT. 
R 
P 
Q 
S 
T 
U 
QT interval 
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Measurement of the QT interval 
The QT interval is traditionally measured manually using lead II, V5 or V6 in the 12-lead ECG.45 
Manual measurements of QT interval are usually done using manual annotations, today often 
done with on-screen computerised methods.45 Modern electrocardiographs have software 
with the ability to automatically measure the QT interval, but manual ECG readings remain the 
golden standard for measuring the QT interval. Automatic measurements are associated with 
larger variability than manual measurements and the variability is dependent on pathological 
conditions affecting the ECG.46,47 Therefore the use of automatic methods should be 
supplemented by manual review of the measurements.45 In a study by Molnar et al.48 the 
reproducibility of automatic measurements of QT was significantly improved when 
supplemented by manual review. The PhysioNet/Computers in Cardiology Challenge on QT 
interval estimation also revealed superiority of manual readings opposed to automatic 
algorithms, although some automatic algorithms came close to the performance of manual 
readings.49 Nevertheless, QT interval measurement carries a large degree of subjectivity 
(manual measurements) or unexplained variability (automatic measurements).50 Especially in 
the presence of odd morphologies including biphasic T wave, large U waves and fused T-U 
waves is the accurate measurement of QT interval difficult.50 This is especially the case during 
e.g. hypokalaemia where large U waves and fused T-U waves are seen as shown in Figure 4. 
Hypokalaemia is present during hypoglycaemia which makes measurements of QT interval 
during hypoglycaemia difficult. 
 
Figure 4. Lead V3 at different levels of serum potassium but similar heart rates. a: 4.6 mmol/l, b: 3.1 
mmol/l, c: 2.7 mmol/l, d: 2.6 mmol/l.
50
 
The end of the T wave is formally defined as the return of the terminal limb to the isoelectric 
baseline, as defined by manual annotation (MA).45 This definition also applies in presence of a 
distinct U wave, however when the T and U waves are fused it must be interpreted as either a 
biphasic T wave or an early occurring U wave. If the former then the QT interval is measured to 
the end of the TU-complex but if the latter the QT interval is measured to the nadir between 
the T and U wave.45,51 As seen in Figure 5 this distinction becomes increasingly difficult to define 
as the U wave occurs closer to the T wave. In studies of changes in the QT interval during 
hypoglycaemia a frequently used method for measuring the QT interval is the ‘slope intersect’ 
(SI) method.27,52,53,23 With this method the end of the T wave is determined as the intersection 
between the isoelectric line and a tangent fitted to the steepest part of the terminal limb of 
the T wave. The SI method has gained popularity because of its simplicity, reduced subjectivity 
and ease of implementation in an automatic algorithm. It is however evident that the method 
consistently underestimates the QT interval46 and is sensitive to the amplitude of the T wave.47 
Low amplitude T waves cause an increased variability and overestimation of QT with the SI 
method.47 
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Figure 5. a: Lead V3 from a normal person. b-e: Theoretical constructions of fused T-U wave 
morphologies as the U wave occurs earlier. The vertical line indicates the notch between the T and U 
wave while the tangents as used in the SI method are also shown.
50
 
Ireland et al.54 studied the differences between the SI method and the MA method during 
hypoglycaemia where fused T-U waves are common. They found that the SI method 
underestimated the QT interval at baseline and overestimated the QT at hypoglycaemia. 
Nevertheless, they recommended the use of the SI method when investigating changes in the 
QT interval during hypoglycaemia because the method is less subjective and provides greater 
distinction between euglycaemia and hypoglycaemia.54 
The heart rate corrected QT interval - QTc 
The QT interval changes with the heart rate – the higher heart rate the shorter QT interval. 
Ideally, investigations of the effect of a drug or condition on the QT intervals should be done at 
a constant heart rate. While this might be possible with measurements on the same subjects it 
is difficult to do when studies involve several subjects.  
To be able to compare the QT intervals at different heart rates it is therefore necessary to 
calculate the heart rate corrected QT interval (QTc). The QTc is obtained by a formula that 
normalises the QT interval to the expected equivalent at an RR interval of 1 second (a heart 
rate of 60 bpm). The RR interval is the distance between two consecutive R peaks in the ECG. 
The RR interval is thus the instantaneous heart rate but usually the average RR interval over a 
number of beats is used for heart rate correction. The correction formula can be based on 
several models of QT-RR relationship including linear[1], Parabolic[2], logarithmic[3] and 
exponential[4] models: 
)( RRaQTQTc  1  [1] 
aRRQTQTc /  [2] 
)ln(RRaQTc   [3] 
)/( eeaQTc RR 1   [4] 
The most widely used formula in studies investigating changes in the QT interval is the square 
root formula by Bazett55 [5]. 
2
1
RRQTQTc /  [5] 
Bazett’s formula has gained popularity mainly due to its simplicity but is frequently criticised 
for its tendency to overcorrect the QT interval at high heart rates and undercorrect it at lower 
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heart rates.45,56,57 The cube root formula by Fridericia58 [6] is often stated as being superior to 
Bazett’s formula45,59 but in a study by Rautaharju56, Fridericias formula was found to have the 
worst performance in comparison with several multiparametrical formulas (Bazett’s formula 
was the next worst formula).  
3
1
RRQTQTc /  [6] 
The Framingham formula60[7] and the Karjalainen nomogram method31 are two additional 
heart rate correction methods frequently used. 
)RR(.QTQTc  1541  [7] 
The performance of all the mentioned formulas suffer from the fact that the QT/RR 
relationship is highly individual and thus no universal heart rate correction formula can give 
exact corrections of QT intervals in all subjects.57 If the heart rates are within a narrow range 
around 60 bpm most correction formulas give satisfactory results. However if the heart rates 
are low or high, the errors from a given universal correction formula can result in erroneous 
results and conclusions. The problem can be mitigated by using subject specific heart rate 
correction formulas – i.e. correction formulas that are fitted to the individual placebo QT/RR 
data points. However, this procedure requires QT/RR data points in a certain range of heart 
rates which are not available in most studies. In Figure 6 the QT/RR data points from two 
different subjects are shown. It is seen how Bazett’s formula overcorrects the QTc at high 
heart rates (short RR Intervals) in one subject (left) while a good correction is obtained in 
another subject (right).  
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Figure 6. QT/QTc vs. RR interval relationship using Bazett’s (QTcB), Fridericia’s (QTcF), and a linear 
subject-specific method (QTcN) for euglycaemic measurements from subject 1 (left) and subject 7 
(right). On the left, overcorrection of Bazett’s formula is seen at low RR intervals (high heart rate), 
while Fridericia’s formula is closer to the subjects specific method. The opposite is seen on the right 
side, where Fridericia’s formula undercorrects the QTc, while Bazett’s formula is closer to the subject 
specific method.  
Changes in QTc during hypoglycaemia 
The most common method for investigating changes in the QT interval during hypoglycaemia 
is the glucose clamp technique, where the blood glucose is clamped at either euglycaemia or 
hypoglycaemia using a constant intravenous infusion of insulin and a variable infusion of 
glucose.61 Table 3 summarises the findings of eight studies of the effect of hypoglycaemia on 
the QT interval. The study populations include both healthy subjects, subjects with T1DM and 
subjects with T2DM. Marques21 found a significant prolongation of the QTc during 
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hypoglycaemia of 583 [425–620] ms (median [range]) compared 429 [411–445] ms during 
euglycaemia in subjects with T1DM. A prolongation of this magnitude has however not been 
reproduced by other studies of patients with T1DM. Lee et al. showed a QTc prolongation from 
407±34 at euglycaemia to 448±34 ms at hypoglycaemia in T1DM subjects. On the other hand 
Koivikko and colleagues62 found a QTc of 410±31 at euglycaemia and 419±35 ms at 
hypoglycaemia, also in subjects with T1DM. In studies of healthy subjects the QTc during 
euglycaemia is typically 399-406 ms increasing to 450-480 ms during hypoglycaemia. Studies 
using both Bazett’s and Fridericia’s formulas indicate that the former might produce higher 
increases in QTc during hypoglycaemia than the latter, possibly indicating an overcorrection of  
the QT interval at the typically higher heart rates during hypoglycaemia.27,62 It should be noted 
that the first five studies in the table are done by the same study group headed by Simon R. 
Heller. These studies in general show longer QT interval prolongations during hypoglycaemia 
than other studies. 
Table 3. Studies of changes in the QTc during euglycaemic and hypoglycaemic glucose clamps. 
Study Population 
QT 
Method 
HR 
Correction 
Euglycaemia Hypoglycaemia 
QTc
a
 ∆QTc
b
 QTc
c
 ∆QTc
d
 
Marques
21
 T1DM MA Bazett 429 18 583 162 
Robinson
23
 Healthy SI Bazett 400 20 450 70 
Robinson
53
 Healthy SI Bazett 406 16 480 90 
Lee
52
 T1DM SI Fridericia 407 16 448 57 
Ireland
54
 Healthy SI Bazett 399 7 459 67 
MA Bazett 414 -5 446 27 
Koivikko
62
 T1DM MA Bazett 410 10 419 13 
Fridericia 397 4 403 5 
Healthy 
 
Bazett 428 8 448 32 
Fridericia 426 11 440 22 
Laitinen
27
 Healthy SI Bazett 408 9 429 30 
Fridericia 399 7 417 25 
Landstedt- 
Hallin
63
 
T2DM MA Bazett 438 11 491 61 
   Mean: 412 10 452 49 
a
QTc [ms] measured at the end of euglycaemic clamp 
b
Change in QTc [ms] from baseline to the end of euglycaemic clamp 
c
QTc [ms] measured at the end of hypoglycaemic clamp 
d
Change in QTc [ms] from baseline to the end of hypoglycaemic clamp 
Methodology for studying hypoglycaemia 
While the glucose clamp technique provides excellent control and reproducibility it is not a 
realistic model of the clinical spontaneous hypoglycaemic episode experienced by persons with 
T1DM. Only a few studies have investigated the change in QTc during episodes of spontaneous 
hypoglycaemia in T1DM. Murphy et al.25 studied the QTc in children and adolescents with 
T1DM during the night in an in-hospital setting where hourly blood samples were drawn 
during the night. During nights with hypoglycaemia (<3.5mmol/l) QTc was 412±22 ms 
compared to 401±19 ms during nights with no hypoglycaemia. In a similar setting with adult 
subjects, Robinson and colleagues24 found an increase in QTc from baseline to nights with 
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hypoglycaemia (<2.5 mmol/l) of 27±15 ms whereas the increase from baseline to nights with 
no hypoglycaemia was 9±19 ms. Using Holter and CGM technology, Gill et al.28 found a QTc on 
nights with hypoglycaemia (<3.5mmol/l) of 445±40 ms versus 415±23 ms on nights with no 
hypoglycaemia (>3.5mmol/l). 
Mechanisms of changes in QTc during hypoglycaemia 
Changes in QTc during hypoglycaemia are thought to be governed by two mechanisms: The 
sympatho-adrenal response to hypoglycaemia causing a release of catecholamines (adrenaline 
and noradrenaline) and lowered potassium concentration caused by elevated insulin and 
adrenaline levels.64  Studies using both healthy subjects and subjects with T1DM have shown 
that blocking the effect of the catecholamines using a beta-blocker largely prevents QTc 
prolongation during hypoglycaemia.52,23 Robinson and colleagues23 found that infusion of 
potassium only reduced the QTc prolongation during hypoglycaemia slightly and concluded 
that QTc prolongation during hypoglycaemia was primarily caused by adrenaline.  
However in the study by Murphy et al.25 of spontaneous episodes of hypoglycaemia, 
adrenaline concentrations did not increase during nights with hypoglycaemia compared with 
nights without hypoglycaemia. Therefore the increase in QTc during hypoglycaemia in this 
study was more likely due to lowering of potassium.   
Aim of PhD study 
Changes in cardiac repolarisation during hypoglycaemia in T1DM are still far from being well 
understood. Although rare, the dead-in-bed syndrome is still a feared condition by people with 
diabetes. It is thus of importance to clarify the pathophysiological mechanisms.  
 
Recent studies show no62 or modest27 increases in QTc during insulin induced hypoglycaemia 
whereas other studies show marked23,52,53,54,63 or very large21 increases in QTc. We suspect that 
methodological issues including QT measurement and heart rate correction may partly explain 
the differences.  
 
Studies on cardiac repolarisation during spontaneous episodes of hypoglycaemia are few and 
are limited by difficulties in study design including the need for overnight sampling of blood 
glucose. The use of modern techniques including digital Holter and CGM might give a better 
insight into the changes in cardiac repolarisation during hypoglycaemia. 
 
The glucose clamp technique for investigating changes in cardiac repolarisation does not 
resemble clinical episodes of hypoglycaemia. If, instead, hypoglycaemia was induced by a 
subcutaneous injection of insulin, the development of hypoglycaemia would resemble a 
spontaneous episode of hypoglycaemia more and at the same time enable controlled 
conditions. 
  
We have previously published a physiological model of the effect of blood glucose and exercise 
on adrenaline.65 Adrenaline constitutes together with potassium the main mechanisms behind 
the alterations in cardiac repolarisation. A physiological model of plasma potassium during 
hypoglycaemia might gain further insight into the dynamics of changes in cardiac 
repolarisation during hypoglycaemia. 
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Aims 
The aim of the PhD thesis is thus to: 
 Investigate the impact of different QT measurement techniques and heart rate 
correction methods on the QTc during hypoglycaemia 
 Investigate changes in the QTc during spontaneous episodes of hypoglycaemia using 
Holter and CGM technology 
 Investigate changes in QTc during simulated spontaneous episodes of hypoglycaemia 
by inducing hypoglycaemia by a subcutaneous injection of insulin. 
 Investigate modelling approaches to gain further insight into the physiology behind 
ECG alterations during hypoglycaemia 
Hypotheses 
The hypotheses are: 
1. The SI and MA techniques for measuring the QT interval can lead to different 
conclusions regarding the prolongation of QT during hypoglycaemia (investigated in 
Paper I). 
2. Different methods of heart rate correction produce significantly different results when 
estimating the change in QTc from euglycaemia to hypoglycaemia (investigated in 
Paper I+II+III). 
3. Spontaneous episodes of hypoglycaemia cause prolongation of QTc during 
hypoglycaemia (investigated in Paper II). 
4. Hypoglycaemia induced by subcutaneous injection of insulin causes a prolongation of 
the QT interval (investigated in Paper III). 
5. It is possible to model changes in potassium during episodes of hypoglycaemia 
(investigated in Paper IV). 
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DISCUSSION AND CONCLUSIONS 
Several studies have reported a prolongation of the QTc during hypoglycaemia which has been 
seen as an indication of hypoglycaemia-induced cardiac arrhythmia being responsible for the 
‘dead-in-bed’ syndrome. In the present PhD project we have investigated several issues 
regarding the changes in the QTc interval during hypoglycaemia. 
QT measurement  
In Paper I we compared two methods, the semi-automatic slope-intersect technique and the 
manual annotation for measuring the QT interval. The two methods produced very different 
results. The slope-intersect method showed a significant increase in QTc corrected by Bazett’s 
formula (QTcB) during hypoglycaemia of 40 ms while the increase using the manual annotation 
was merely 7 ms. The fact that two acknowledged methods for measuring the QT interval can 
differ to such a degree clearly shows one of the issues associated with the QT interval as a 
parameter for quantifying cardiac repolarisation. Part of the explanation of the differences 
between the two methods can be found in the morphological change of the ECG during 
hypoglycaemia and hyperinsulinaemia. Hypoglycaemia and hyperinsulinaemia both cause a 
lowering of extracellular potassium known to reduce T wave amplitude and to cause 
pronounced U waves. The low amplitude T waves and U waves make it more difficult to 
measure the end of the T wave and when the slope-intersect method is employed an 
overestimation of the end of the T-wave is difficult to avoid. The advantage of the slope-
intersect method over the manual annotation is that it is much easier to define resulting in 
lower inter-observer differences.1 It cannot from our results be concluded which method is the 
more correct. As long as a detailed description of the methodology for measuring the QT 
interval is provided, the reader can incorporate it in the interpretation of the result. So when 
e.g. the slope-intersect method is used to measure the QT interval during the insulin induced 
hypoglycaemia it is known that the result might overestimate the actual QT prolongation due 
to hypokalaemia. For this reason, proprietary fully automatic QT measurement techniques as 
used in some studies of hypoglycaemia2,3 can make the interpretation of the results difficult.  
 
In Paper II and Paper III we decided to use the slope-intersect method for two reasons. First, 
the method is easy to implement in a computer algorithm which increased the speed of data 
analysis significantly. Second the manual measurements as used in Paper I were expensive and 
not readily available. Third and most important, the majority of studies of QT interval changes 
during hypoglycaemia employ the slope-intersect method. The results from Paper I indicate 
that comparing results from studies using different QT interval measurement techniques is 
associated with uncertainties. By using the slope-intersect method in our investigations 
comparisons of our results to the literature can be made with a higher degree of certainty.  
Spontaneous hypoglycaemia 
In Paper II we investigated the change in QTc during spontaneous hypoglycaemia in an 
ambulant setting using a CGM and a high resolution digital Holter monitor. We suspected that 
previous findings of modest QTc prolongation during spontaneous hypoglycaemia4,5 could 
partly be caused by overcorrection of Bazett’s formula. In accordance with the literature we 
found a significant albeit modest increase in QTcB of 11 ms. However, using other popular 
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correction methods including the allegedly superior subject specific correction (QTcS) we did 
not find a significant increase in QTc. As we included all measurements of hypoglycaemia in 
our analysis and not only measurements of nocturnal hypoglycaemia our results can not be 
directly compared with previous studies. However, the difference in heart rate between 
euglycaemia and hypoglycaemia is stated in none of the studies of spontaneous 
hypoglycaemia.2,3,4,5 Thus, overcorrection of Bazett’s formula can not be ruled out as an 
explanation of the observed difference in QTc between euglycaemia and hypoglycaemia. Our 
findings regarding heart rate correction in Paper II are supported by the results in Paper I and 
partly by the results in Paper III. In Paper I the increase in QTcB using the manual annotation 
method is significant while the increase in QTcF is not. In Paper III there is a significant 
increase in both QTcB and QTcF, however the increase in QTcF is smaller than the increase in 
QTcB. Since it was not possible in these studies to calculate QTcS, we do not know if the 
difference between Bazett’s and Fridericia’s formula is overcorrection by the former or 
undercorrection by the latter. However the results underline the problems associated with 
heart rate correction in studies of hypoglycaemia. 
Subcutaneous insulin induced hypoglycaemia 
Paper III describes a novel way of investigating physiological changes during induced 
hypoglycaemia that resembles clinical episodes of hypoglycaemia. The study filled a gap 
between the hyperinsulinaemic glucose clamp technique and the observational studies of 
spontaneous hypoglycaemia. The clamp technique provides reproducible episodes of 
hypoglyaemia with low variability but uses supraphysiological levels of insulin and does not 
resemble clinical episodes of hypoglycaemia. On the other hand, true spontaneous episodes of 
hypoglycaemia are difficult to investigate because a large number of participants are needed 
(to obtain a sufficient number of episodes), the episodes have great variability and it is difficult 
to obtain controlled conditions. In Paper III, to fill this gap, we used subcutaneous 
administration of insulin to induce hypoglycaemia in adults with T1DM. The amount of insulin 
was realistic and the changes in blood glucose thus resembled a clinical episode of 
hypoglycaemia. The method allowed us to do true control episodes where all conditions were 
held equal except the blood glucose which was maintained at euglycaemia by administration 
of glucose. The results from the study showed that the increase in QTcB from baseline to 
hypoglycaemia was 30 ms of which 18 ms could be attributable to hypoglycaemia per se when 
correcting for other factors using the control episode. With QTcF the prolongation attributable 
to hypoglycaemia was 11 ms. The results from Paper III also showed that while the decrease in 
potassium caused QTc prolongation during both hypoglycaemia and control, the likely 
mechanism for the additional prolongation during hypoglycaemia was mediated by an increase 
in adrenaline levels. Thus, the results indicate that hypoglycaemia induced by a subcutaneous 
bolus of insulin causes QT interval prolongation but that the prolongation is not of the 
magnitude seen in most clamp studies. 
 
The design of the study in Paper III is not without issues. We chose a design where the amount 
of insulin was adjusted to the fasting glucose and the estimated insulin sensitivity. The 
estimations were carried out by an experienced diabetologist and the resulting blood glucose 
levels during hypoglycaemia were within target in all but one case. The alternative to the 
chosen approach would be to use a constant dose of e.g. 0.15 U/kg. We did not choose this 
approach because we wanted the episodes to resemble spontaneous episodes with insulin 
levels as realistic as possible. If we had used a constant dose of 0.15 U/kg it would have 
resulted in higher insulin concentrations and in many cases glucose infusion would be 
required. The fact that the amount of insulin was estimated does however make the design of 
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the study more difficult to reproduce. We chose not to randomise the hypoglycaemia control 
sequence because we wanted the procedures during the control episodes to be carried out 
exactly as during the hypoglycaemia day. This would not be possible if the control sequence 
were first, as the time of hypoglycaemia following insulin injection would be unknown. The 
close proximity of hypoglycaemia and control was not optimal. The design with only one day 
between hypoglycaemia and control was chosen to reduce the number of study visits and 
required time to run the study. A longer period between the two visits would mean that an 
additional visit was required since one CGM sensor only lasts 72 hours. However, the 
significant change in baseline blood glucose, QTcB and QTcF could indicate that one day 
between hypoglycaemia and control was too short. 
Physiological modelling of potassium 
In Paper IV we describe the, to our knowledge, first attempt to model changes in the 
potassium during episodes of hypoglycaemia. As we showed in Paper III, potassium plays a 
major role in the change of cardiac repolarisation during insulin-induced hypoglycaemia. A 
physiological model of potassium thus provides a way to analyse the physiology behind the 
changes in cardiac repolarisation during hypoglycaemia. The model in general simulated 
potassium levels accurately although the test material for the model was limited. Our initial 
idea was to combine the potassium model with a model of adrenaline as we have previously 
published.6 When we are able to model the effect of hypoglycaemia on both hypokalaemia 
and adrenaline, we might be able to simulate the potential effect of hypoglycaemia on cardiac 
repolarisation in a wide range of situations. Another possibility would be to simulate the 
changes QTc based on measured or simulated potassium and adrenaline levels. 
 
The model was built solely on data obtained from the literature by decoding graphs. As such 
the model becomes only as accurate as the data used for estimating the model parameters. 
Also the use of the potassium model in people with diabetes might prove difficult because of 
variations in insulin sensitivity that could affect the stimulatory effect of insulin on potassium 
levels.  
 
An obvious next step would be to use the data from Paper III in further tests and development 
of the potassium model and the adrenaline model. This would enable better modelling and 
hopefully deeper understanding of the physiological mechanisms responsible for the QT 
interval prolongation during hypoglycaemia 
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Conclusions 
The aim of the present thesis was to investigate the change in repolarisation and QTc during 
both induced and spontaneous hypoglycaemia as well as to understand the underlying 
physiology. In addition, I wanted to investigate how the methodology of measuring the QT 
interval, heart rate correcting the QT interval and inducing hypoglycaemia affected the change 
in QTc during hypoglycaemia. To answer these questions two studies were designed (Paper II 
and Paper III) and data from a previous study (Paper I) was used. The conclusions to the 
hypotheses tested are: 
Hypothesis 1: Conclusion: 
The semi-automatic slope intersect  and the 
manual annotation techniques for measuring 
the QT interval can lead to different 
conclusions regarding the prolongation of QT 
during hypoglycaemia 
Yes, indeed. In one of the studies slope-
intersect method showed a QTc prolongation 
of 40 ms, while the manual annotation 
method showed a prolongation of 7ms. Both 
methods have advantaged but comparisons of 
studies using the different methods should be 
done with caution. 
Hypothesis 2: Conclusion: 
Different methods of heart rate correction 
produce significantly different results when 
estimating the change in QTc from 
euglycaemia to hypoglycaemia. 
Yes, in two of our studies the use of Bazett’s 
formula resulted in different conclusions than 
the use of Fridericia’s formula. In one study 
the two formulas produced different degrees 
of prolongation but resulted in the same 
conclusion. It is not clear whether this 
difference is due to overcorrection by Bazett’s 
or undercorrection by Fridericia’s formula. 
We recommend the use of both formula and 
a subject specific formula when possible. 
Hypothesis 3: Conclusion: 
Spontaneous episodes of hypoglycaemia 
cause prolongation of QTc during 
hypoglycaemia. 
Yes and no, spontaneous hypoglycaemia in 
our study cause changes in the QTcB, but not 
QTcF or QTcS. We therefore conclude that the 
increase in QTcB during spontaneous 
hypoglycaemia may be due to overcorrection 
by Bazett’s formula.  
Hypothesis 4: Conclusion: 
Hypoglycaemia induced by subcutaneous 
injection of insulin cause a prolongation of the 
QT interval. 
 
Yes, we observed significant changes in both 
QTcB and QTcF during hypoglycaemia after 
controlling for other factors using control 
episodes.  
Hypothesis 5: Conclusion: 
It is possible to model changes in potassium 
during episodes of hypoglycaemia 
 
Yes, we developed a model of potassium 
changes during hypoglycaemia that was 
reasonably accurate. However, further 
validation of the model is needed on more 
episodes of hypoglycaema. 
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